JP7857235B2 - 慢性腎疾患を処置または防止するための方法 - Google Patents

慢性腎疾患を処置または防止するための方法

Info

Publication number
JP7857235B2
JP7857235B2 JP2022575895A JP2022575895A JP7857235B2 JP 7857235 B2 JP7857235 B2 JP 7857235B2 JP 2022575895 A JP2022575895 A JP 2022575895A JP 2022575895 A JP2022575895 A JP 2022575895A JP 7857235 B2 JP7857235 B2 JP 7857235B2
Authority
JP
Japan
Prior art keywords
compound
therapeutically effective
dibromo
benzofuran
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022575895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529691A5 (cg-RX-API-DMAC10.html
JP2023529691A (ja
Inventor
イェー,リテイン
イェン,シュンチー
イェン,ロンチ
シェン,ザンツォン
Original Assignee
アースローシ セラピューティクス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アースローシ セラピューティクス,インク. filed Critical アースローシ セラピューティクス,インク.
Publication of JP2023529691A publication Critical patent/JP2023529691A/ja
Publication of JP2023529691A5 publication Critical patent/JP2023529691A5/ja
Application granted granted Critical
Publication of JP7857235B2 publication Critical patent/JP7857235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
JP2022575895A 2020-06-10 2021-06-09 慢性腎疾患を処置または防止するための方法 Active JP7857235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063037469P 2020-06-10 2020-06-10
US63/037,469 2020-06-10
US202163195411P 2021-06-01 2021-06-01
US63/195,411 2021-06-01
PCT/US2021/036620 WO2021252630A1 (en) 2020-06-10 2021-06-09 Methods for treating or preventing chronic kidney disease

Publications (3)

Publication Number Publication Date
JP2023529691A JP2023529691A (ja) 2023-07-11
JP2023529691A5 JP2023529691A5 (cg-RX-API-DMAC10.html) 2024-06-10
JP7857235B2 true JP7857235B2 (ja) 2026-05-12

Family

ID=78846498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575895A Active JP7857235B2 (ja) 2020-06-10 2021-06-09 慢性腎疾患を処置または防止するための方法

Country Status (10)

Country Link
US (1) US20230218563A1 (cg-RX-API-DMAC10.html)
EP (1) EP4164624A4 (cg-RX-API-DMAC10.html)
JP (1) JP7857235B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230024354A (cg-RX-API-DMAC10.html)
AU (1) AU2021288679A1 (cg-RX-API-DMAC10.html)
CA (1) CA3181902A1 (cg-RX-API-DMAC10.html)
IL (1) IL298833A (cg-RX-API-DMAC10.html)
MX (1) MX2022015678A (cg-RX-API-DMAC10.html)
TW (1) TW202214228A (cg-RX-API-DMAC10.html)
WO (1) WO2021252630A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ.ベー. 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
JP2019524747A (ja) 2016-07-18 2019-09-05 アースローシ セラピューティクス,インク. 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2019195118A1 (en) * 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2020070539A1 (en) * 2018-10-01 2020-04-09 Astrazeneca Ab Compositions for reducing serum uric acid
JP2022511800A (ja) * 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA3140412A1 (en) * 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ.ベー. 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
JP2019524747A (ja) 2016-07-18 2019-09-05 アースローシ セラピューティクス,インク. 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法

Also Published As

Publication number Publication date
KR20230024354A (ko) 2023-02-20
US20230218563A1 (en) 2023-07-13
MX2022015678A (es) 2023-03-14
EP4164624A1 (en) 2023-04-19
IL298833A (en) 2023-02-01
EP4164624A4 (en) 2024-10-16
TW202214228A (zh) 2022-04-16
AU2021288679A1 (en) 2023-02-02
WO2021252630A1 (en) 2021-12-16
CA3181902A1 (en) 2021-12-16
JP2023529691A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2011201520B2 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
JP2025004090A (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
US20230218563A1 (en) Methods for treating or preventing chronic kidney disease
AU2026202224A1 (en) Compound for treating gout or hyperuricemia
EA022395B1 (ru) Соединение пиперидинила в качестве модулятора активности хемокинового рецептора
CN115916208A (zh) 用于治疗肌肉萎缩症的方法和组合物
CN103889420A (zh) 新盐及医药用途
CN111840112B (zh) 鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
US11427590B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
JP2024525897A (ja) 変形性関節症の治療におけるnlrp3阻害剤の投与計画
CN116648445A (zh) 治疗或预防慢性肾脏病的方法
CZ300429B6 (cs) Lécivo ke zmírnení deprese nebo úzkostných stavu
HK40096745A (en) Methods for treating or preventing chronic kidney disease
WO2023083139A1 (zh) 一种电荷平衡的复合物、其制备方法及其用途
EP2890687B1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
HK40085850A (en) Methods and compositions for the treatment of muscular dystrophy
JP2006528155A (ja) 3,7−ジアザビシクロ[3.3.1]ノナン化合物の、ヒト男性患者の抗不整脈事象治療及び/又は予防のための使用
WO2025255532A1 (en) Combination therapies
WO2025080937A1 (en) Compositions with psilocybin and psilocin derivatives
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260424

R150 Certificate of patent or registration of utility model

Ref document number: 7857235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150